Health Catalyst Q2 revenue up 6%, CEO to retire

Health Catalyst

07/08/2025 21:13

Overview

Health Catalyst Q2 2025 revenue grows 6% yr/yr to $80.7 mln

Adjusted EBITDA for Q2 beats analyst expectations, per LSEG data

CEO Dan Burton to retire June 2026, will assist in transition

Outlook

Health Catalyst expects Q3 revenue of approximately $75 mln

Company forecasts Q3 adjusted EBITDA of approximately $10.5 mln

Health Catalyst anticipates full-year revenue of approximately $310 mln

Company projects full-year adjusted EBITDA of approximately $41 mln

Result Drivers

TECHNOLOGY REVENUE - Technology revenue increased to $52.9 mln, up from $47.6 mln yr-ago

PROFESSIONAL SERVICES - Professional services revenue slightly declined to $27.8 mln from $28.3 mln yr-ago

GOODWILL IMPAIRMENT - Significant goodwill impairment impacted net loss, resulting in a $40.978 mln loss

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Technology Revenue
$80.72 mln
Q2 Net Income
-$40.98 mln
Q2 Adjusted EBITDA
Beat
$9.34 mln
$8.30 mln (12 Analysts)
Q2 Adj. Technology Gross Margin
50.0%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the software peer group is "buy"

Wall Street's median 12-month price target for Health Catalyst Inc is $6.50, about 41.2% above its August 6 closing price of $3.82

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 12 three months ago

Press Release: ID:nGNX5vHQRj

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)